Navigation Links
Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays

- PathHunter eXpress Kits Combined with LabChip Microfluidic Instruments Provide a Comprehensive, High Quality, Easy-to-Use GPCR Assay Solution -

HOPKINTON, Mass. and FREMONT, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) and DiscoveRx, today announced the commercial availability of PathHunter(TM) eXpress Beta-Arrestin kits for use with Caliper's LabChip(R) 3000 and EZ Reader(TM) platforms to conduct cellular G protein-coupled receptor (GPCR) assays. This milestone is part of the collaboration between Caliper and DiscoveRx, announced in May 2008, to provide a powerful and comprehensive suite of solutions to assist pharmaceutical and biotechnology researchers in more efficiently discovering new drugs.

"This joint solution enables researchers to quickly assess potency and potential side effects of new drug candidates in a cellular environment, which accelerates overall drug discovery programs," said Nate Cosper, Director of Marketing at Caliper Life Sciences. "Achievement of this commercial milestone underscores Caliper's commitment to partnering with leading technology companies like DiscoveRx to develop innovative solutions that provide higher quality and more reproducible data, improve scientific workflows and enable novel research approaches."

Caliper's LabChip 3000 and EZ Reader platforms, a suite of instruments for screening and profiling potential drug candidates, utilize microfluidic separation and direct detection of both substrates and products to generate high quality, reproducible data to qualify potential lead candidates. Caliper provides researchers in neuroscience, cardiovascular, and inflammation therapeutic areas with platforms and services for target validation, receptor screening, side effect profiling, functional cellular assays, in vivo efficacy studies using IVIS technology, and in vivo pharmacodynamic analysis.

"PathHunter eXpress Beta-Arrestin kits for use with Caliper's LabChip instruments contain everything needed to perform screening or profiling experiments: cells, detection reagents, media and plates. The workflow improvements inherent to this complete solution for live-cell GPCR experiments enables scientists to spend more of their time designing better and safer drugs," said Sailaja Kuchibhatla, Senior Vice President of Business Development at DiscoveRx. "Today's announcement further signifies the momentum generated by our partnership with Caliper and the relationships they are helping us develop with customers in secondary screening and profiling laboratories."

About DiscoveRx Inc.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of Beta-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. For more information on DiscoveRx products, please visit

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit

Caliper, LabChip, and EZ Reader are trademarks of Caliper Life Sciences, Inc.

DiscoveRx and PathHunter are trademarks of DiscoveRx Corporation.

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
2. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
3. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Caliper Life Sciences Reports Second Quarter 2008 Results
6. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
7. Caliper Life Sciences Added to Russell 3000(R) Index
8. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
9. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
10. Caliper Life Sciences Reports West Coast Consolidation of Operations
11. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
Post Your Comments:
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):